Companies /Healthcare
Insmed Inc
NASDAQ: INSM Biotechnology
$121.86
▼ $1.02 (−0.83%) today
Markets closed · 4:51pm ET

Insmed (INSM) Q3 2026 Earnings

Reported Oct 29, 2026, 7:01am ET · SEC source
$-0.46
Miss −21.50%
EPS · est. $-0.38 GAAP

Includes a $7.5 million change in fair value of contingent consideration liabilities and $5.1 million amortization of intangible assets (vs. $104.7 million contingent consideration charge in Q3 2025)

$524.4M
Beat +4.99%
Revenue · est. $499.5M
1 quarter
Consecutive EPS misses

How Did INSM Stock React to Q3 2026 Earnings?

% change · around the report
−12%−6%0+6%Oct 29Oct 30report 7:01am ETearnings−2.0%+2.0%
−12%−6%0+6%Oct 29Oct 30earnings−2.0%+2.0%
INSM +2.0%S&P 500 −2.0%
−12%−6%0+6%Oct 29Oct 30report 7:01am ETearnings−4.1%+2.0%
−12%−6%0+6%Oct 29Oct 30earnings−4.1%+2.0%
INSM +2.0%NASDAQ −4.1%
−12%−6%0+6%Oct 28Nov 5report 7:01am ETearnings−5.0%+0.5%
−12%−6%0+6%Oct 28Nov 5earnings−5.0%+0.5%
INSM +0.5%S&P 500 −5.0%
−12%−6%0+6%Oct 28Nov 5report 7:01am ETearnings−10.1%+0.5%
−12%−6%0+6%Oct 28Nov 5earnings−10.1%+0.5%
INSM +0.5%NASDAQ −10.1%
+15.06%
Day of report
+0.89%
Next session
−2.54%
One week

Did INSM Beat Earnings? Q3 2026 Results

No. Insmed reported Q3 2026 earnings of $-0.46 a share on Oct 29, 2026, missing the $-0.38 consensus estimate by 21.5%. Revenue was $524.4M against a $499.5M estimate.

Insmed delivered a split verdict in the third quarter of 2026, beating revenue expectations handily while falling short on the bottom line. Total revenue of $524.43 million exceeded the $499.48 million consensus by 4.99% and surged 268.4% year over year, powered almost entirely by BRINSUPRI, its oral DPP1 inhibitor for non-cystic fibrosis bronchiectasis, which alone contributed $400.10 million, up 29% sequentially from the second quarter. On the earnings side, GAAP EPS came in at $-0.46, missing the $-0.3786 consensus by 21.50%; that figure includes a $7.5 million charge from the change in fair value of contingent consideration liabilities and $5.1 million in intangible asset amortization, though both were far smaller than the $104.7 million contingent consideration charge that weighed on the year-ago period. Investors had been watching closely for evidence of organic growth beyond the initial launch surge, and the strong sequential BRINSUPRI number offered a clear answer. Looking ahead, management raised the low end of full-year BRINSUPRI guidance to $1.35 billion to $1.40 billion and now expects to reach cash flow positivity in 2027 without additional capital.

Key Takeaways
  • BRINSUPRI revenue grew 29% sequentially, driven by strong U.S. growth
  • ARIKAYCE revenue grew 9% YoY, driven by 21% international growth
  • Cost of product revenues fell to 14.9% of revenue from 20.6% due to lower-cost BRINSUPRI mix
  • R&D rose to $270.0 million on TPIP manufacturing and clinical costs and headcount
  • SG&A rose to $253.0 million on BRINSUPRI commercial activities
  • Lower contingent consideration fair-value charge ($7.5 million vs $104.7 million) narrowed operating loss
  • Cash burn lower than recent quarters on higher revenue and financial discipline

“The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline.”

Insmed CEO, on the earnings call

What Is Insmed's Outlook?

Insmed raised the low end of its full-year 2026 revenue guidance for both commercial products. - **BRINSUPRI:** guidance is now $1.35–$1.4 billion, previously $1.25–$1.4 billion. It excludes meaningful Japan contribution in 2026. Gross-to-net guidance is unchanged at mid- to high-20%s. - **ARIKAYCE:** guidance is now $460–$470 million, previously $450–$470 million. It excludes contribution from any potential label expansion in 2026. Gross-to-net guidance is unchanged at low- to mid-20%s. The company reiterated peak sales estimates of more than $7 billion for BRINSUPRI, more than $6 billion for TPIP and more than $1 billion for ARIKAYCE. It forecasts a collective CAGR above 20% for these three assets over the next 10+ years. It expects to reach cash flow positivity in 2027 without additional capital, assuming no material expansion of the expense base from business development. Q4 2026 investment will increase for clinical programs and Japan commercial infrastructure, including $50 million of anticipated AstraZeneca milestone payments. Upcoming milestones: - ARIKAYCE PDUFA date of January 28, 2027, and a PMDA submission in Q4 2026, with expanded-label launches in the U.S. and Japan targeted for 1H 2027. - TPIP PALM-ILD enrollment completion in 1H 2028 and IPF Phase 3 initiation in 1H 2027. - Phase 2 starts for INS1033 (RA) and INS1148 (IPF) in 2027. - First gene therapy data in 2027. - One to two INDs per year, with pre-clinical research kept below 20% of expenditures.

INSM YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$200.0M$400.0M$142.3M$524.4MRevenue$-49,937,975$-89,369,000Operating Income$-58,024,756$-100,319,000Net Income
$0$200.0M$400.0MRevenueOperating IncomeNet Income
INSM income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $524.4M $142.3M +268.4%
Operating Income −$89.4M −$49.9M +79.0%
Net Income −$100.3M −$58.0M +72.9%

INSM Revenue by Segment

BRINSUPRI$400.1M+1,323.8%
ARIKAYCE$124.4M+9.0%
ARIKAYCE U.S.
ARIKAYCE International

INSM Revenue by Geography

United States$473.6M+364.0%
Rest of World$50.8M+26.0%
Japan
Europe & Rest of World

Figures from SEC filings and company reports. Not investment advice.